Kurt Yuqin Qing, MD
Neurology · Orange
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Regents of the University of Claifornia Univ Neursciences · 72 clinicians in this group
Looking this up.
Hospitals listed: Uci Health-Orange. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Qing’s office at (714) 456-7004 to ask if they take your plan before you enroll.
California Medical Board record
Licence A173650 · Current
Licensed to practise in California · since 2021 · expires 2027-07-31 · Indiana University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Uci Health-OrangeOrange, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of Chao Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.44 (3.82 to 7.06) · 2,934 cases, Jul 2022 – Jun 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 82.98 (46.2 to 119.76) · 170 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.422, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.56, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.547, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.356, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.449, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.6 to 1) · 1,287 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Uci Health-Orange
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 4 better, 4 the same, 0 worse of 8 measures. Readmissions: 2 better, 7 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.44 (3.82 to 7.06) · 2,934 cases | Worse | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 82.98 (46.2 to 119.76) · 170 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.422 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.56 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.547 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.356 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.449 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1) · 1,287 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.25 to 1.87) · 2,297 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.9 (0.67 to 1.13) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 59 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.2 · 104 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.3 · 331 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.1 · 416 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 330 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,269 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.33) · 8,263 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.19 (0.01 to 0.37) · 8,703 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.95 (0.57 to 3.32) · 1,647 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.52 (1.33 to 3.71) · 2,756 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.15 (2.82 to 11.48) · 1,643 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.78 (2.24 to 7.33) · 1,680 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.98 (0.61 to 3.36) · 871 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.28 (0 to 0.77) · 7,232 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.5 · 170 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 0.546 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 165 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.8 · 556 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 75.5 · 113 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 0 · 391 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -4.4 · 436 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 556 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.1 to 6.6) · 846 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.8 (10 to 14) · 846 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.8 · 200 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.9 · 64 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21 · 110 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 10.8 (8.6 to 13.8) · 2,457 cases | No different | Jan 2022 – Dec 2024 |
What patients said (575 patients answered, 16% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 81% |
| Patients who gave a rating of "9" or "10" (high) | 65% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 40% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$36,332
Medicare paid this office $36,332 for 157 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | 45 | $17,071 | $169 |
| Long return visit (40+ min) | 23 | $3,306 | $107 |
| Return visit (30+ min) | 30 | $2,868 | $72 |
| Measurement of brain wave activity with video (veeg), 2-12 hours with review and report by health care professional | 13 | $1,443 | $111 |
| Measurement of brain wave activity (eeg), awake and asleep | 25 | $1,150 | $46 |
See all 6 services
| Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | 45 | $17,071 | $169 |
| Long return visit (40+ min) | 23 | $3,306 | $107 |
| Return visit (30+ min) | 30 | $2,868 | $72 |
| Measurement of brain wave activity with video (veeg), 2-12 hours with review and report by health care professional | 13 | $1,443 | $111 |
| Measurement of brain wave activity (eeg), awake and asleep | 25 | $1,150 | $46 |
| Measurement of brain wave activity (eeg), awake and drowsy | 17 | $753 | $44 |
Who their Medicare patients are
157 Original Medicare patients in 2024. Average age 66 · Under 65 35% · 85 and older 13% · Women 50% · Also on Medicaid 66% · Health risk score 2.66. Sicker patients than 9 in 10 peers; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 75% · Stroke 49% · Depression 40% · Diabetes 39% · Chronic kidney disease 36% · Coronary heart disease 32% · Dementia 29% · Heart failure 27% · COPD 24% · Atrial fibrillation 23% · Cancer 19%.
The office billed $201,599, Medicare allowed $47,354 and paid $36,332; for 331 services of 27 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 157 | 331 | 66 | 2.66 | $201,599 | $36,332 |
| 2023 | 75 | 127 | 59 | 1.81 | $97,826 | $14,869 |
| 2022 | 11 | 21 | 54 | 1.80 | $6,469 | $2,187 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | 15 | $4,779 | $171 |
| Long return visit (40+ min) | 30 | $3,788 | $108 |
| Return visit (30+ min) | 12 | $1,223 | $82 |
Medicaid work
$12,175 in 2024
Medicaid paid $12,175 for 98 billed services this clinician did in 2024, up to 19 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, each increment of greater than 12 hours, up to 26 hours of EEG recording, interpretation and report after each 24-hour period; with video (VEEG) | 24 | $5,811 |
| Return visit (30+ min) | 55 | $4,014 |
| Long return visit (40+ min) | 19 | $2,350 |
| 2024 | 98 | 3 | 19 | $12,175 |
| 2023 | 12 | 1 | 12 | $916 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 12 | $916 |
Drugs they prescribed that Part D paid
$383,276
Pharmacies billed $383,276 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 849) in 2024. At or below the middle of the specialty; the typical neurology clinician is at 0%.
654 generic and 161 brand-name prescriptions · $383,276 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Briviact | 82 | $127,059 | $1,549 |
| Epidiolex | 27 | $95,755 | $3,546 |
| Lamictal Xr | 12 | $29,909 | $2,492 |
| Lacosamide | 110 | $15,866 | $144 |
| Felbamate | 36 | $13,335 | $370 |
See all 16 drugs
| Briviact | 82 | $127,059 | $1,549 |
| Epidiolex | 27 | $95,755 | $3,546 |
| Lamictal Xr | 12 | $29,909 | $2,492 |
| Lacosamide | 110 | $15,866 | $144 |
| Felbamate | 36 | $13,335 | $370 |
| Levetiracetam | 93 | $4,334 | $47 |
| Clobazam | 55 | $4,085 | $74 |
| Oxcarbazepine | 23 | $3,046 | $132 |
| Divalproex Sodium Er | 28 | $1,807 | $65 |
| Zonisamide | 47 | $1,734 | $37 |
| Lamotrigine | 124 | $1,705 | $14 |
| Divalproex | 18 | $657 | $36 |
| Phenobarbital | 34 | $344 | $10 |
| Topiramate | 23 | $210 | $9 |
| Clonazepam | 32 | $110 | $3 |
| Lorazepam | 12 | $49 | $4 |
Year by year
| 2024 | 849 | 73 | 0% (0) | 19% | $383,276 |
| 2023 | 237 | 46 | 0% (0) | None | $116,914 |
| 2022 | 75 | 18 | 0% (0) | None | $9,647 |
| 2021 | 20 | None | 0% (0) | None | $8,316 |
| 2020 | 38 | None | 0% (0) | None | $2,800 |
| 2018 | 73 | 18 | 0% (0) | None | $3,117 |
| 2017 | 20 | None | 0% (0) | None | $4,313 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Briviact | 13 | $33,765 | $2,597 |
| Lacosamide | 33 | $10,045 | $304 |
| Levetiracetam | 42 | $3,428 | $82 |
| Clobazam | 17 | $2,355 | $139 |
| Divalproex Sodium Er | 12 | $1,253 | $104 |
| Lamotrigine | 33 | $623 | $19 |
2022: 3 drugs
| Levetiracetam | 15 | $756 | $50 |
| Gabapentin | 14 | $451 | $32 |
| Lamotrigine | 16 | $244 | $15 |
2020: 1 drug
| Atorvastatin | 14 | $141 | $10 |
Money from drug and device companies
$3,031 in 2025
| 2025 | 4 | 32 | None | $3,031 |
| 2024 | 4 | 23 | None | $2,370 |
| 2023 | 3 | 3 | None | $578 |
| 2022 | 3 | 3 | None | $638 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Jazz Pharmaceuticals | Epidiolex | $1,443 | 11 payments
|
| Ucb | Fintepla | $608 | 6 payments
|
| Neuropace | Rns Neurostimulator Kit | $588 | 10 payments
|
| SK Life Science | None | $393 | 5 payments
|
See all 32 published payments
| Neuropace | Meals · 2025-12-19 | Rns Neurostimulator Kit | $30 |
| SK Life Science | Meals · 2025-12-07 | None | $82 |
| Neuropace | Meals · 2025-12-07 | Rns Neurostimulator Kit | $45 |
| Ucb | Meals · 2025-12-06 | None | $54 |
| Neuropace | Meals · 2025-12-06 | Rns Neurostimulator Kit | $43 |
| Neuropace | Meals · 2025-12-06 | Rns Neurostimulator Kit | $84 |
| Neuropace | Meals · 2025-12-06 | Rns Neurostimulator Kit | $68 |
| Neuropace | Meals · 2025-12-06 | Rns Neurostimulator Kit | $22 |
| Ucb | Meals · 2025-11-20 | None | $84 |
| Ucb | Meals · 2025-11-20 | Fintepla | $120 |
| Neuropace | Meals · 2025-11-14 | Rns Neurostimulator Kit | $11 |
| Jazz Pharmaceuticals | Meals · 2025-09-13 | Epidiolex | $70 |
| Jazz Pharmaceuticals | Meals · 2025-09-13 | Epidiolex | $49 |
| Jazz Pharmaceuticals | Meals · 2025-09-13 | Epidiolex | $28 |
| Jazz Pharmaceuticals | Meals · 2025-09-13 | Epidiolex | $28 |
| Jazz Pharmaceuticals | Travel · 2025-09-12 | Epidiolex | $341 |
| Jazz Pharmaceuticals | Travel · 2025-09-12 | Epidiolex | $256 |
| Jazz Pharmaceuticals | Travel · 2025-09-12 | Epidiolex | $244 |
| Jazz Pharmaceuticals | Meals · 2025-09-12 | Epidiolex | $175 |
| Jazz Pharmaceuticals | Meals · 2025-09-12 | Epidiolex | $49 |
| Jazz Pharmaceuticals | Meals · 2025-08-20 | Epidiolex | $85 |
| Neuropace | Meals · 2025-06-14 | Rns Neurostimulator Kit | $100 |
| SK Life Science | Meals · 2025-06-11 | None | $43 |
| Ucb | Meals · 2025-05-14 | Fintepla | $78 |
| Jazz Pharmaceuticals | Meals · 2025-05-08 | Epidiolex | $118 |
| Ucb | Meals · 2025-04-17 | None | $147 |
| SK Life Science | Meals · 2025-04-06 | None | $137 |
| SK Life Science | Meals · 2025-04-06 | None | $36 |
| Neuropace | Meals · 2025-04-06 | Rns Neurostimulator Kit | $92 |
| Neuropace | Meals · 2025-04-06 | Rns Neurostimulator Kit | $92 |
| Ucb | Meals · 2025-02-12 | Fintepla | $125 |
| SK Life Science | Meals · 2025-02-06 | None | $96 |
See earlier years (2024, 2023, 2022)
2024: $2,370
| Neuropace | Rns Neurostimulator Kit | $1,595 | 16 payments
|
| SK Life Science | None | $430 | 4 payments
|
| Jazz Pharmaceuticals | Epidiolex | $272 | 2 payments
|
| Ucb | Fintepla | $73 | 1 payment
|
2023: $578
| Neuropace | Rns Neurostimulator Kit | $267 | 1 payment
|
| Catalyst Pharmaceuticals | Fycompa | $177 | 1 payment
|
| SK Life Science | None | $134 | 1 payment
|
2022: $638
| Ceribell | Ceribell Rapid Response Eeg | $500 | 1 payment
|
| SK Life Science | Xcopri | $87 | 1 payment
|
| Neuropace | Rns Neurostimulator Kit | $51 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1659806610
- Licence
- CA A173650California A173650: Current · expires 2027-07-31
- Trained
- Indiana University School of Medicine, 2017
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2084E0001X (2084E0001X); Neurology (2084N0400X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2017-04-27
- NPI last updated
- 2024-09-25
- NPI record certified
- 2024-09-25
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1300 York Ave, New York, NY, 10065 · 300 Pasteur Dr, Stanford, CA, 94305